RCS - Skinvisible Pharma - Skinvisible Submits Transdermal Obesity Patent
29/05/2024 12:45
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240529:nRSc1915Qa&default-theme=true
RNS Number : 1915Q Skinvisible Pharmaceuticals, Inc 29 May 2024
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal
Treatment
Administration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists
Enhanced by Invisicare Topical / Transdermal Delivery System
LAS VEGAS, NV / ACCESSWIRE / May 29, 2024 / Skinvisible Pharmaceuticals, Inc.
("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative pharmaceutical
research and development company, announced a major advancement in the battle
against obesity. The Company has achieved a significant milestone by
officially filing a provisional patent application covering formulations that
leverage the Company's proprietary delivery technology Invisicare(®) for the
transdermal administration of obesity drugs. Titled "Transdermal Delivery
Composition for Delivery of CB-1 Receptor Antagonists and/or GLP-1 Receptor
Agonists, and Method of Delivery," this patent filing ushers in a new era of
efficient and convenient obesity drug delivery solutions.
The patent application focuses on Invisicare; a patented transdermal delivery
technology designed to incorporate CB-1 receptor antagonists and/or GPL-1
receptor agonists, two classes of drugs known for their potential in obesity
management, into a lotion that is applied topically to the skin using a
metered applicator. Studies have demonstrated the superior transdermal
penetration and controlled release of other active compounds using
Invisicare's innovative technology; with certain actives exhibiting up to a
tenfold increase in transdermal delivery effectiveness. By utilizing
Invisicare, Skinvisible aims to not only offer patients a convenient and
effective alternative to traditional oral or injectable therapies but to also
enhance drug efficacy and potentially significantly reduce side effects as
transdermal delivery avoids first-pass metabolism. Additionally, for long-term
treatment of obesity, a transdermal delivery system could feasibly provide a
convenient method for administering maintenance doses of anti-obesity
medications.
The global obesity drug market is poised to exceed $30 billion by 2027,
propelled by the escalating prevalence of obesity worldwide and the eagerly
anticipated advent of revolutionary anti-obesity medications. Nonetheless, the
impediment posed by needles and injections remains a formidable barrier to
access and compliance. Skinvisible's proprietary transdermal delivery
technology overcomes this obstacle, unlocking the full therapeutic potential
of CB-1 and GLP-1 targeting drugs.
"Our transdermal technology has the potential to revolutionize how obesity
drugs are administered, granting patients access to potent weight loss
medications through the ease and convenience of a metered dose of lotion
simply applied to the skin," remarked Terry Howlett, CEO of Skinvisible
Pharmaceuticals. "This needle-free approach holds immense promise in enhancing
treatment adherence and broadening the accessibility of obesity therapies to
countless individuals grappling with weight-related challenges." He added,
"This groundbreaking patent application highlights our proficiency in
transdermal delivery and underscores our commitment to leveraging this
capability to reshape treatment standards."
Skinvisible is actively pursuing strategic partnerships with pharmaceutical
and/or biotech companies to facilitate the introduction of the first
transdermal obesity therapies to market and to explore the application of its
delivery platform across diverse disease domains.
For more information on Skinvisible Pharmaceuticals, partnerships and
investment opportunities, please visit www.skinvisible.com
(https://pr.report/c-95Khtz) or contact info@skinvisible.com.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals, a wholly-owned subsidiary of Skinvisible, Inc.,
is a pioneering research and development company specializing in licensing
proprietary topical and transdermal formulations utilizing its patented
polymer skin delivery system; Invisicare. This innovative technology provides
life-cycle management and distinctive enhancements for both topical and
transdermal delivery products. Invisicare formulated as a lotion or cream,
effectively adheres active ingredients to the skin facilitating a controlled
release of the active to and/or through the skin and into the blood stream
over time. Skinvisible has recently developed formulations for the potential
treatment of obesity, along with over forty dermatology related conditions
including rare skin disorders. For further details, please visit
www.skinvisible.com (https://pr.report/P8hxVC7d) .
Forward-Looking Statements: This press release contains 'forward looking'
statements within the meaning of Section 21A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
and are subject to the safe harbors created thereby including with respect to
the possible development of any such products, the acceptance of any such
products in the market place, the size of any such markets, the ability of any
product candidates to be approved by the U.S. Food and Drug Administration
among others. Such statements involve certain risks and uncertainties
associated with an emerging company. Actual results could differ materially
from those projected in the forward-looking statements as a result of risk
factors discussed in Skinvisible, Inc. reports on file with the U.S.
Securities and Exchange Commission (including, but not limited to, a report on
Form 10Q for the period ending March 31, 2024).
###
Contacts:
Strategic Partnerships: Doreen McMorran - doreen@invisicare.com
Corporate Inquiries: info@skinvisible.com Office Number: 702-433-7154 (PST)
SOURCE: Skinvisible, Inc.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAFIFLLETIAFIS